10.27.26 -- Advancing Cell Therapy Toward A Functional Cure For T1D With Forthcoming BetaNova's Jonathan Rigby And Will Rust, Ph.D.

Industry experts unpack post-thaw processing bottlenecks, focusing on critical quality control sampling and the technical hurdles of scaling automated cell thawing operations.

Modular vector platforms blend custom transfection with gentle purification. Optimized TFF plus precise chromatography yield high vector recovery across diverse cell and gene therapy applications.

Achieve large-scale, end-to-end cell and gene therapy manufacturing with an automation system for cost-effective formulation and filling.

It's important to identify and monitor the critical quality attributes of products to ensure safety and efficacy. View a range of orthogonal methods to understand and define the CQAs of AAV products.

Learn how electroporation technology improves gene editing efficiency, reduces cell death, and enables scalable workflows for cell therapy, screening, and bioproduction in this informative webinar.

In episode 139, Host Erin Harris talks to Jonathan Rigby, President and CEO of Sernova and Will Rust, PhD, President and CEO of Seraxis. Sernova and Seraxis are coming together to form BetaNova, combining Sernova’s implantable Cell Pouch with Seraxis’ stem cell-derived pancreatic islet cells in an effort to develop a functional cell therapy for people living with Type 1 diabetes (T1D).

How will AI, digital twins, and synthetic control arms change real-world evidence? Explore how better data can help cell and gene therapies show long-term value.